Evidence map›Paper›PMID 32874095›Full record

ArticleTobacco use insights2020

Patient-Level Factors Associated with Oncology Provider-Delivered Brief Tobacco Treatment Among Recently Diagnosed Cancer Patients.

J M Neil, S N Price, E R Friedman, C Ponzani, J S Ostroff, A Muzikansky, E R Park

Open access · goldAbstract read
In one paragraph

Article in Tobacco use insights, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Tobacco Assessment in Actively Accruing National Cancer Institute Clinical Trials Network Trials.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025
    Article
  2. Article
  3. Long-term follow-up of smokers following lung and colorectal cancer diagnosis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

J M NeilHarvard Medical School/Massachusetts General Hospital, Boston, MA, USA.ORCID https://orcid.org/0000-0001-5769-4961
S N PriceUniversity of Arizona, Tucson, AZ, USA.
E R FriedmanVanderbilt University, Nashville, TN, USA.
C PonzaniHarvard Medical School/Massachusetts General Hospital, Boston, MA, USA.
J S OstroffMemorial Sloan Kettering Cancer Center, New York City, NY, USA.
A MuzikanskyHarvard Medical School/Massachusetts General Hospital, Boston, MA, USA.
E R ParkHarvard Medical School/Massachusetts General Hospital, Boston, MA, USA.
Harvard University · USMemorial Sloan Kettering Cancer Center · USUniversity of Arizona · USVanderbilt University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Integrating Tobacco Treatment into Cancer CareR01CA166147 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PARK, ELYSE R. · 2012 to 2016
$3.6M
Examining Delivery of Integrated Tobacco Treatment in Cancer CareK24CA197382 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PARK, ELYSE R. · 2015 to 2019
$841k
NCI NIH HHS K24 CA197382NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA166147
6 · The paper itself

Abstract

backgroundA cancer diagnosis is seen as a "teachable moment" for patients to consider changing their behavioral risk factors, such as smoking. It also offers an opportunity for oncology providers to engage in a dialogue about how they can support patients changing their smoking behaviors. Brief, evidence-based tobacco cessation treatment delivered by oncology providers through the 5As (Ask, Advise, Assess, Assist Arrange) model is recommended, but provision to cancer patients remains suboptimal.

aimExplore patient-level factors associated with 5As receipt among current smokers with a newly diagnosed cancer.

methodA total of 303 patients self-reported whether they received each of the 5As during their most recent oncology care visit. Multivariable regression analyses were conducted to identify patient-level factors associated with 5As receipt.

resultsOncology provider-delivered 5As rates ranged from 81.5% (Ask) to 30.7% (Arrange). 5As receipt was associated with: reporting lower illness-related stigma, diagnosis of a comorbid smoking-related disease, diagnosis of a smoking-related cancer, and diagnosis of a non-advanced cancer.

conclusionFindings support previous literature in which smoking-related diagnoses were associated with greater receipt of 5As; however, disparities in the receipt of 5As existed for patients with more advanced cancer diagnoses and illness-related stigma. Inequities in the provision of quit assistance may further decrease treatment effectiveness and survival expectancy among certain patient populations. These findings are, therefore, important as they identify specific patient-level factors associated with lower 5As receipt among newly diagnosed cancer patients.

Indexed as

5Ascancer diagnosisdisparitiessmokingstigma

Identifiers

PMID32874095
PMCPMC7436840
OpenAlexW3068852763

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.